Core Points - Yiming Pharmaceutical (002826) announced the transfer of 43.8559 million shares, representing 23% of the company's total shares, from Gao Fan to Beijing Fuhai Enterprise Management Partnership [2] - Following this transfer, Beijing Fuhai will become the controlling shareholder of the company, with the actual controller changing from Gao Fan to Yao Jinbo [2]

（文章来源：每日经济新闻） 易明医药（SZ 002826，收盘价：25.74元）8月20日晚间发布公告称，公司控股股东由高帆变更为北京 福好，实际控制人由高帆变更为姚劲波。 2025年1至6月份，易明医药的营业收入构成为：药品销售占比99.71%，其他占比0.58%，药品推广服务 占比-0.29%。 ...

每经AI快讯，8月20日，易明医药(002826.SZ)公告称，公司原控股股东、实际控制人高帆将持有的4386 万股公司股份（占上市公司股份总数的23.00%）协议转让给北京福好，过户日期为2025年8月19日。本 次权益变动完成后，北京福好将持有公司4386万股股份（占上市公司股份总数的23.00%），公司控股 股东由高帆变更为北京福好，实际控制人由高帆变更为姚劲波。 ...

资金流向方面，今日主力资金净流入7824.78万元，占比成交额15.8%。其中，超大单净流入2035.88万 元、占成交额4.11%，大单净流入5788.90万元、占成交额11.69%，中单净流出流入1491.08万元、占成 交额3.01%，小单净流出9315.86万元、占成交额18.81%。 通过天眼查大数据分析，西藏易明西雅医药科技股份有限公司共对外投资了6家企业，参与招投标项目 10次，知识产权方面有商标信息11条，专利信息16条，此外企业还拥有行政许可15个。 易明医药最新一期业绩显示，截至2025中报，公司营业总收入3.11亿元、同比减少11.52%，归属净利润 3755.71万元，同比减少5.27%，扣非净利润2502.22万元，同比增长102.33%，流动比率2.688、速动比率 2.474、资产负债率23.32%。 天眼查商业履历信息显示，西藏易明西雅医药科技股份有限公司，成立于2007年，位于拉萨市，是一家 以从事批发业为主的企业。企业注册资本19067.775万人民币，实缴资本7491.4792万人民币。公司法定 代表人为许可。 金融界消息 截至2025年8月19日收盘，易明医药（0028 ...

Core Insights - Yiming Pharmaceutical (SZ002826) reported a decline in both revenue and net profit for the first half of 2025, with revenue at 311.45 million yuan, down 11.52% year-on-year, and net profit attributable to shareholders at 37.56 million yuan, down 5.27% year-on-year [1][2]. Financial Performance - Revenue for the reporting period was 311,445,583.30 yuan compared to 351,984,809.03 yuan in the same period last year, reflecting an 11.52% decrease [2]. - Net profit attributable to shareholders was 37,557,144.18 yuan, down from 39,646,165.15 yuan, marking a 5.27% decline [2]. - Net profit after deducting non-recurring gains and losses was 25,022,156.54 yuan, which represents a significant increase of 102.33% from 12,366,829.01 yuan in the previous year [1][2]. - The net cash flow from operating activities was 62,458,414.18 yuan, an increase from 46,131,657.93 yuan year-on-year [2]. - Basic and diluted earnings per share were both 0.20 yuan, down from 0.21 yuan [2]. - The weighted average return on equity was 4.96%, slightly down from 5.30% [2]. Asset and Equity Position - Total assets at the end of the reporting period were 1,005,255,294.07 yuan, up from 926,469,234.87 yuan at the end of the previous year [2]. - Net assets attributable to shareholders were 764,048,582.94 yuan, an increase from 739,003,677.36 yuan [2]. Executive Compensation - The vice president of Yiming Pharmaceutical, Gao Ying, received a salary of 701,500 yuan, which is higher than the chairman's salary of 681,600 yuan and the general manager's salary of 614,300 yuan [1][2].

Core Viewpoint - 易明医药's stock closed at 23.35 yuan on August 15, experiencing a decline of 0.15 yuan or 0.64% from the previous trading day [1] Company Performance - For the first half of 2025, 易明医药 reported a revenue of 311 million yuan, representing a year-on-year decrease of 11.52% [1] - The net profit attributable to shareholders was 37.56 million yuan, down 5.27% year-on-year [1] - The company signed a compensation agreement with performance commitment parties, involving an amount of 14.43 million yuan [1] Market Activity - On August 15, the net inflow of main funds into 易明医药 was 19.95 million yuan, accounting for 0.49% of the circulating market value [1] - Over the past five days, the cumulative net inflow of main funds reached 199 million yuan, representing 4.89% of the circulating market value [1]

（文章来源：证券日报） 证券日报网讯 8月14日晚间，易明医药发布公告称，2025年半年度公司实现营业收入311，445，583.30 元，同比下降11.52%；归属于上市公司股东的净利润为37，557，144.18元，同比下降5.27%。 ...

2025年8月15日，易明医药(002826.SZ)发布2025年半年度报告。截至2025年8月14日，共有1个机构投资 者披露持有易明医药A股股份，合计持股量达168.00万股，占易明医药总股本的0.88%。其中，机构投 资者包括中证乾元资本管理有限公司-中证乾元三号私募证券投资基金，机构投资者合计持股比例达 0.88%。相较于上一季度，机构持股比例合计上涨了0.13个百分点。 公募基金方面，本期较上一季未再披露的公募基金共计1个，即诺安多策略混合A。 外资态度来看，本期较上一季未再披露的外资机构即MORGAN STANLEY & CO. INTERNATIONAL PLC.。 ...

易明医药2025半年报 ...

证券日报网讯 8月14日晚间，易明医药发布公告称，公司第三届董事会第二十六次会议审议通过了《关 于公司的议案》等多项议案。 （文章来源：证券日报） ...